Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | AOC1 | P19801 | 2/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24448624 | 0.86 | RPS6KA3 (0.41) | RPS6KA3ALOX5AOC1AOC3GSK3B | |
| SCHEMBL26030475 | 0.86 | RPS6KA3 (0.45) | RPS6KA3ALOX5AOC1AOC3GSK3B | |
| SCHEMBL25996380 | 0.86 | RPS6KA3 (0.45) | RPS6KA3ALOX5AOC1AOC3GSK3B | |
| SCHEMBL24448462 | 0.86 | RPS6KA3 (0.41) | RPS6KA3ALOX5AOC1AOC3GSK3B | |
| SCHEMBL18557486 | 0.83 | TSHR (0.39) | RPS6KA3ALOX5AOC1AOC3LMNA | |
| SCHEMBL24481241 | 0.83 | TSHR (0.44) | RPS6KA3ALOX5AOC1AOC3LMNA | |
| SCHEMBL6408659 | 0.82 | RPS6KA3 (0.44) | RPS6KA3ALOX5AOC1AOC3GABRA1 | |
| SCHEMBL31651702 | 0.80 | GAA (0.43) | RPS6KA3ALOX5AOC1AOC3GABRA1 | |
| SCHEMBL31188403 | 0.80 | SIRT3 (0.41) | RPS6KA3ALOX5AOC1AOC3CYP3A4 | |
| SCHEMBL2737302 | 0.80 | RPS6KA3 (0.43) | RPS6KA3ALOX5AOC1AOC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024138045-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20070237947-A1 | Superhydrophobic fibers produced by electrospinning and chemical vapor deposition | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070173501-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173500-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070010668-A1 | Pyrimidine compounds | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-01-11 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | RPS6KA3 2247/4885ALOX5 3524/4885AOC1 4339/4885 |
| US-20070010668-A1 | Pyrimidine compounds | TYMS, TYMP, DPYD | RPS6KA3 1713/4885ALOX5 1242/4885AOC1 942/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | RPS6KA3 355/4885ALOX5 3837/4885AOC1 3222/4885 |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | ADH1C, SIK1, PKN2 | RPS6KA3 760/4885ALOX5 2498/4885AOC1 447/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | RPS6KA3 627/4885ALOX5 4680/4885AOC1 2797/4885 |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | RPS6KA3 1352/4885ALOX5 4376/4885AOC1 3669/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | RPS6KA3 2136/4885ALOX5 2390/4885AOC1 592/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | RPS6KA3 2572/4885ALOX5 4249/4885AOC1 3415/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | RPS6KA3 4523/4885ALOX5 219/4885AOC1 1476/4885 |
| US-20070173501-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | DSTYK, CDK2, ERBB2 | RPS6KA3 333/4885ALOX5 2437/4885AOC1 3502/4885 |
| US-20070173500-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | DSTYK, CDK2, ERBB2 | RPS6KA3 333/4885ALOX5 2437/4885AOC1 3502/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | RPS6KA3 2900/4885ALOX5 4310/4885AOC1 4042/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | RPS6KA3 2648/4885ALOX5 977/4885AOC1 4768/4885 |
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | RPS6KA3 140/4885ALOX5 4153/4885AOC1 3466/4885 |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | TRPM2, TRPM8, TRPM7 | RPS6KA3 3833/4885ALOX5 2639/4885AOC1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.